Epidemiology and outcomes of NET in a Portuguese cancer center

#3926

Introduction: NET make up 0.5% of all cancer diagnosis in Europe. They range from indolent to highly aggressive tumors and may cause a wide range of functional symptoms. Phase III trials are difficult because of poor accrual in a heterogenous group of rare tumors.

Aim(s): We present data of a Portuguese cancer center.

Materials and methods: Retrospective study of NET discussed in MDT between 01/2019 and 12/2022. Patient selection included: age >18 years; histological confirmation of giNET or NET of unknown primary; treatment at our cancer center. Patient characteristics (age, gender), characteristics of disease (location, grade, functional symptoms), performed treatments (surgery, systemic therapy) and outcomes were collected off patient records. Statistical analysis was performed with R.

Conference:

Presenting Author: Magno S

Authors: Magno S, Esteves S, Leite V, Claro I, Pereira D,

Keywords: neuroendocrine, epidemiology, portugal, outcomes,